BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...This article has been updated to correct Lee's role on the MorphoSys board. By BioCentury StaFF Corinne...
...and president of the U.S. business organization at Amgen Inc. (NASDAQ:AMGN). Cancer and autoimmune diseases play MorphoSys AG...
...his successor arrives, at which time he will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen...
BioCentury | Nov 13, 2020
Deals

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

...By STEPHEN HANSEN, ASSOCIATE EDITOR AND JEFF CRANMER, EXECUTIVE EDITOR A Cherry in MorphoSys’ hunt for new...
...platform to discover and develop T cell engaging therapeutics against up to six undisclosed targets. MorphoSys’...
...and gene therapy.TargetsENPP2 (ATX) - autotaxin BC Staff BBT-877 Affimed Roivant Sciences Insilico Medicine Inc. Johnson & Johnson Bridge Biotherapeutics Boehringer Ingelheim Cevec Pharmaceuticals GmbH MorphoSys ElevateBio...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...remain on the company’s board. Jens Holstein will step down as CFO and board member at MorphoSys AG...
...Hsieh was president and CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Deep...
BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

...in Europe (see “MorphoSys Nets $900M”).Under the deal, MorphoSys...
...and MorphoSys is eligible for tiered royalties.While MorphoSys’...
...MorphoSys.Kress added that over the long term MorphoSys...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...counsel. Previously, he held the same position at IQVia Holdings Inc. (NYSE:IQV). Veracyte also added MorphoSys AG...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...Kress’ first big deal with U.S. approval FDA granted accelerated approval to Monjuvi tafasitamab-cxix from MorphoSys AG...
...was the subject of the first major deal under MorphoSys’ new CEO Jean-Paul Kress (see “MorphoSys...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...ExeVir CEO Torsten Mummenbrauer told BioCentury. Mummenbrauer held BD roles at Hookipa Pharma Inc. (NASDAQ:HOOK), MorphoSys AG...
BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

...lung cancer. EMA accepts tafasitamab MAA EMA accepted an MAA from Incyte Corp. (NASDAQ:INCY) and MorphoSys AG...
...Survival of motor neuron 2 centromeric Robin Sawka, BioCentury Staff Kadmon Holdings Inc. Sorrento Therapeutics Inc. Novartis AG AveXis Inc. Incyte Corp. MorphoSys AG Zentalis...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...Vicromax, its COVID-19 therapy (see “FDA Green-Lights More Than 70 COVID-19 Trials” ). Cancer company MorphoSys AG...
...Sawka, BioCentury Staff Frazier Healthcare Partners BioMarin Pharmaceutical Inc. Dicerna Pharmaceuticals Inc. Zogenix Inc. ADC Therapeutics S.A. Personal Genome Diagnostics Inc. Immunic Inc. MorphoSys AG Emergent...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

...follow in the footsteps of other European mAb developers like Genmab A/S (CSE:GMAB; NASDAQ:GMAB) and MorphoSys AG...
Items per page:
1 - 10 of 854
BioCentury | Jan 8, 2021
Management Tracks

Moderna hires chief commercial officer as it ramps up COVID vaccine rollout; plus MorphoSys, Silence, Verastem, Viking, Destiny and Allen Institute

...This article has been updated to correct Lee's role on the MorphoSys board. By BioCentury StaFF Corinne...
...and president of the U.S. business organization at Amgen Inc. (NASDAQ:AMGN). Cancer and autoimmune diseases play MorphoSys AG...
...his successor arrives, at which time he will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen...
BioCentury | Nov 13, 2020
Deals

Nov. 12 Quick Takes: MorphoSys, UCB bring in new tech via deals; plus Cevec-Roche, Bridge-BI, Affimed-Roivant, Insilico-J&J, TCR2-ElevateBio

...By STEPHEN HANSEN, ASSOCIATE EDITOR AND JEFF CRANMER, EXECUTIVE EDITOR A Cherry in MorphoSys’ hunt for new...
...platform to discover and develop T cell engaging therapeutics against up to six undisclosed targets. MorphoSys’...
...and gene therapy.TargetsENPP2 (ATX) - autotaxin BC Staff BBT-877 Affimed Roivant Sciences Insilico Medicine Inc. Johnson & Johnson Bridge Biotherapeutics Boehringer Ingelheim Cevec Pharmaceuticals GmbH MorphoSys ElevateBio...
BioCentury | Oct 1, 2020
Management Tracks

CVS’s Asgarian joins Thrive as CMO; plus Black Diamond names Ingram chairman and updates from MorphoSys, G1 and more

...remain on the company’s board. Jens Holstein will step down as CFO and board member at MorphoSys AG...
...Hsieh was president and CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Deep...
BioCentury | Sep 16, 2020
Product Development

Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

...in Europe (see “MorphoSys Nets $900M”).Under the deal, MorphoSys...
...and MorphoSys is eligible for tiered royalties.While MorphoSys’...
...MorphoSys.Kress added that over the long term MorphoSys...
BioCentury | Aug 1, 2020
Management Tracks

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

...counsel. Previously, he held the same position at IQVia Holdings Inc. (NYSE:IQV). Veracyte also added MorphoSys AG...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

...Kress’ first big deal with U.S. approval FDA granted accelerated approval to Monjuvi tafasitamab-cxix from MorphoSys AG...
...was the subject of the first major deal under MorphoSys’ new CEO Jean-Paul Kress (see “MorphoSys...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

...ExeVir CEO Torsten Mummenbrauer told BioCentury. Mummenbrauer held BD roles at Hookipa Pharma Inc. (NASDAQ:HOOK), MorphoSys AG...
BioCentury | May 22, 2020
Product Development

May 21 Quick Takes: EC approves Zolgensma for SMA; plus Sunovion, Kadmon, Sorrento, tafasitamab, Zentalis’ new JV

...lung cancer. EMA accepts tafasitamab MAA EMA accepted an MAA from Incyte Corp. (NASDAQ:INCY) and MorphoSys AG...
...Survival of motor neuron 2 centromeric Robin Sawka, BioCentury Staff Kadmon Holdings Inc. Sorrento Therapeutics Inc. Novartis AG AveXis Inc. Incyte Corp. MorphoSys AG Zentalis...
BioCentury | Apr 22, 2020
Management Tracks

Hershberg joins Frazier as venture partner; plus Moses to chair LabGenius, and ViralClear, MorphoSys, Emergent and more

...Vicromax, its COVID-19 therapy (see “FDA Green-Lights More Than 70 COVID-19 Trials” ). Cancer company MorphoSys AG...
...Sawka, BioCentury Staff Frazier Healthcare Partners BioMarin Pharmaceutical Inc. Dicerna Pharmaceuticals Inc. Zogenix Inc. ADC Therapeutics S.A. Personal Genome Diagnostics Inc. Immunic Inc. MorphoSys AG Emergent...
BioCentury | Apr 3, 2020
Deals

Servier adds mAb platform via takeout of former European biotech darling Symphogen

...follow in the footsteps of other European mAb developers like Genmab A/S (CSE:GMAB; NASDAQ:GMAB) and MorphoSys AG...
Items per page:
1 - 10 of 854